CAS: 203460-30-4

Potent CaV2.3 calcium channel blocker, selective, voltage-dependent, with 30 nM IC50. Offers antinociceptive effects on C and Aδ fibres.

SNX 482 is a drug that has been shown to be effective against autoimmune diseases, including multiple sclerosis and bowel disease. SNX 482 is an antagonist of voltage-dependent calcium channels. It reduces the influx of calcium ions into cells by blocking the voltage-gated calcium channels responsible for neuronal activity and regulating cellular physiology. This drug also has anti-inflammatory effects on the bowel and reduces glutamate release in the brain, which may be helpful in treating bowel disease.

SNX-482 is a peptide inhibitor that blocks the interaction of receptor and ligand, thus inhibiting the biological response. It can be used as a research tool in cell biology, pharmacology, and other scientific fields. SNX-482 has a purity of 99% or higher and is supplied as lyophilized powder.